Clinical Trial Update: Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of an adjuvanted reduced-dose inactivated polio vaccine given at 6, 10, 14 weeks and 9 months; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• adjuvanted reduced-dose inactivated polio vaccine

Snippet

Sponsor: Statens Serum Institut | Conditions: Poliomyelitis | Phase 3 | Status: COMPLETED